This site is intended for healthcare professionals
News

NICE recommends Lynparza for maintenance treatment of relapsed, platinum-sensitive high grade epithelial ovarian, fallopian tube or peritoneal cancer if they have a BRCA1 or BRCA2 mutation (BRCAm).- AstraZeneca + Merck Inc.

Read time: 1 mins
Published:18th Jan 2020
AstraZeneca and MSD have announced that NICE has expanded its recommendation for Lynparza (olaparib) tablets for women with relapsed, BRCA-mutated, advanced ovarian cancer. Olaparib is now recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of relapsed, platinum-sensitive high grade epithelial ovarian, fallopian tube or peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy if they have a BRCA1 or BRCA2 mutation (BRCAm). Lynpraza will be made available to patients within NHS England and Wales via routine commissioning if they have had three or more courses of platinum-based chemotherapy; and to patients within NHS England via the Cancer Drugs Fund (CDF) if they have had two courses of platinum-based chemotherapy.
Condition: Ovarian Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.